Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. (March 2016)

• Record Type: Journal Article
• Authors: Neeland, Ian J; McGuire, Darren K; Chilton, Robert; Crowe, Susanne; Lund, Søren S; Woerle, Hans J; Broedl, Uli C; Johansen, Odd Erik
• Is Part Of: Diabetes & vascular disease research. Volume 13:Number 2(2016:Mar.)
• Page Start: 119
• Page End: 126
• Publication Date: 2016-03
• Subjects: Obesity -- body fat distribution -- visceral adipose tissue -- empagliflozin -- sodium glucose co-transporter 2 inhibitor; Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/1479164115616901
• Languages: English
• ISSNs: 1479-1641

Abstract

Aims: To determine the effects of empagliflozin on adiposity indices among patients with type 2 diabetes mellitus. Methods: Changes in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12 weeks (cohort 1) or 24 weeks (cohort 2) duration. Results: This study comprised 3300 patients (cohort 1, N = 823; cohort 2, N = 2477). Empagliflozin reduced weight, waist circumference and adiposity indices versus placebo in both cohorts. Adjusted mean (95% confidence interval) change from baseline in empagliflozin versus placebo was −1.7 kg (−2.1 to −1.4 kg) and −1.9 kg (−2.1 to −1.7 kg) for body weight ( p < 0.001); −1.3 cm (−1.8 to −0.7 cm) and −1.3 cm (−1.7 to −1.0 cm) for waist circumference ( p < 0.001); −0.2% (−0.7% to 0.3%; p = 0.45) and −0.3% (−0.7% to 0.0%; p = 0.08) for estimated total body fat; −0.007 (−0.011 to −0.004) and −0.008 (−0.010 to −0.006) for index of central obesity ( p < 0.001); and −0.3 (−0.5 to 0.0; p = 0.07) and −0.4 (−0.7 to −0.1; p = 0.003) for visceral adiposity index in cohorts 1 and 2, respectively. Adipose reductions were seen across most age, sex and waist circumference subgroups. Conclusion: Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.